{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T20:55:59Z","timestamp":1781470559127,"version":"3.54.1"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021T140754, 2020M672521"],"award-info":[{"award-number":["2021T140754, 2020M672521"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010021","name":"Postdoctoral Science Foundation of Central South University","doi-asserted-by":"publisher","award":["248485"],"award-info":[{"award-number":["248485"]}],"id":[{"id":"10.13039\/501100010021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Since most hepatocellular carcinoma (HCC) patients are diagnosed at advanced stages, there is no effective treatment to improve patient survival. Ferroptosis, a regulated cell death driven by iron accumulation and lipid peroxidation, has been reported to play an important role in tumorigenesis. However, the detailed mechanism and biological function of ferroptosis are still incompletely understood in HCC patients. In this study, we analyzed genomic profiles of three HCC datasets, GSE6764, GSE14520, and GSE14323. Venn diagrams were implemented to visualize the overlapping genes between differentially expressed genes and ferroptosis-related gene set. Then, one up-regulated gene, ACSL4, and five down-regulated genes, STEAP3, MT1G, GCH1, HAMP, and CXCL2, were screened. Based on the survival analysis performed by Kaplan-Meier plotter database, ferroptosis-related gene CXCL2 was demonstrated positively-correlated with the patients\u2019 prognosis. Moreover, CXCL2 overexpression significantly inhibited cell growth and improved cellular ROS, Fe<jats:sup>2+<\/jats:sup> and MDA levels in HCC cells Huh7 and MHCC97H, suggesting the roles of CXCL2 in inducing ferroptotic cell death. In addition, aberrantly expressed CXCL2 was negatively associated with malignancy clinical features, such as nodal metastasis and higher grades. The ssGSEA enrichment analysis revealed that CXCL2 co-expressed molecules were mainly involved in inflammation and immune-related pathways, such as acute inflammatory response, humoral immune response, adaptive immune response. TISIDB algorithm indicated the positive correlation between CXCL2 expression and tumor-infiltrating immune cells, including neutrophils and macrophages. Additionally, we also found that CXCL2 was positively correlated with immune infiltration score, and HCC patients with higher score harbored better prognosis. Together, these findings suggested that CXCL2 may enhance ferroptosis sensitivity and regulate immune microenvironment in HCC, and serve as a promising prognosis biomarker for HCC patients.<\/jats:p>","DOI":"10.3389\/fonc.2022.998736","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T05:26:47Z","timestamp":1664947607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Application of genomic selection and experimental techniques to predict cell death and immunotherapeutic efficacy of ferroptosis-related CXCL2 in hepatocellular carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Qiaoli","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuju","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanliang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.188314","article-title":"Challenges in liver cancer and possible treatment approaches","volume":"1873","author":"Anwanwan","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/cancers14010103","article-title":"Lifestyle and hepatocellular carcinoma what is the evidence and prevention recommendations","volume":"14","author":"Zelber-Sagi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021535","article-title":"Treatment of liver cancer","volume":"5","author":"Liu","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-020-01157-x","article-title":"The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.10.011","article-title":"The metabolic underpinnings of ferroptosis","volume":"32","author":"Zheng","year":"2020","journal-title":"Cell Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1904197","DOI":"10.1002\/adma.201904197","article-title":"Recent progress in ferroptosis inducers for cancer therapy","volume":"31","author":"Liang","year":"2019","journal-title":"Adv Mater"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.672904","article-title":"Ferroptosis-related genes in lung adenocarcinoma: Prognostic signature and immune, drug resistance, mutation analysis","volume":"12","author":"Ren","year":"2021","journal-title":"Front Genet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2020.02.009","article-title":"Emerging mechanisms and disease relevance of ferroptosis","volume":"30","author":"Stockwell","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.06.012","article-title":"A physiological function for ferroptosis in tumor suppression by the immune system","volume":"30","author":"Stockwell","year":"2019","journal-title":"Cell Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.02.015","article-title":"Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs","volume":"483","author":"Su","year":"2020","journal-title":"Cancer Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486217","article-title":"Mast cell and macrophage chemokines CXCL1\/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation","volume":"121","author":"De Filippo","year":"2013","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.immuni.2018.09.018","article-title":"Distinct compartmentalization of the chemokines CXCL1 and CXCL2 and the atypical receptor ACKR1 determine discrete stages of neutrophil diapedesis","volume":"49","author":"Girbl","year":"2018","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.367","article-title":"CXCL2\/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2018.51.12.140","article-title":"Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma","volume":"51","author":"Ding","year":"2018","journal-title":"BMB Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21622","article-title":"Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma","volume":"45","author":"Wurmbach","year":"2007","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13046-021-01904-y","article-title":"Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma","volume":"40","author":"Wang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2119\/molmed.2008.00110","article-title":"Genes involved in viral carcinogenesis and tumor initiation in hepatitis c virus-induced hepatocellular carcinoma","volume":"15","author":"Mas","year":"2009","journal-title":"Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.743046","article-title":"Downregulated ferroptosis-related gene STEAP3 as a novel diagnostic and prognostic target for hepatocellular carcinoma and its roles in immune regulation","volume":"9","author":"Yan","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"baaa021","DOI":"10.1093\/database\/baaa021","article-title":"FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations","author":"Zhou","year":"2020","journal-title":"Database (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2196\/27633","article-title":"Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation","volume":"23","author":"Lanczky","year":"2021","journal-title":"J Med Internet Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/ijms22052622","article-title":"TNMplot.com: A web tool for the comparison of gene expression in normal, tumor and metastatic tissues","volume":"22","author":"Bartha","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1090","article-title":"LinkedOmics: analyzing multi-omics data within and across 32 cancer types","volume":"46","author":"Vasaikar","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: an integrated repository portal for tumor-immune system interactions","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-0721-z","article-title":"Large-Scale public data reuse to model immunotherapy response and resistance","volume":"12","author":"Fu","year":"2020","journal-title":"Genome Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104919","article-title":"The application of ferroptosis in diseases","volume":"159","author":"Qiu","year":"2020","journal-title":"Pharmacol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114486","article-title":"Ferroptosis and its potential as a therapeutic target","volume":"186","author":"Yuan","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719175","article-title":"Construction of a ferroptosis-related nine-lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.818453","article-title":"Targeting cancer cell ferroptosis to reverse immune checkpoint inhibitor therapy resistance","volume":"10","author":"Deng","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.03.009","article-title":"Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC","author":"Niu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2016.07.035","article-title":"Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer","volume":"381","author":"Roh","year":"2016","journal-title":"Cancer Lett"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28159","article-title":"Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib","volume":"133","author":"Louandre","year":"2013","journal-title":"Int J Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02523","article-title":"Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis","volume":"3","author":"Dixon","year":"2014","journal-title":"Elife"},{"key":"B49","article-title":"Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors","volume":"34","author":"Lachaier","year":"2014","journal-title":"Anticancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0439-x","article-title":"ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma","volume":"42","author":"Feng","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.04.050","article-title":"The role of CXC chemokines and their receptors in cancer","volume":"267","author":"Vandercappellen","year":"2008","journal-title":"Cancer Lett"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415518111","article-title":"Synchronized renal tubular cell death involves ferroptosis","volume":"111","author":"Linkermann","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.829316","article-title":"Ferroptosis due to cystathionine gamma Lyase\/Hydrogen sulfide downregulation under high hydrostatic pressure exacerbates VSMC dysfunction","volume":"10","author":"Jin","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2004.5.1.11","article-title":"Receiver operating characteristic (ROC) curve: practical review for radiologists","volume":"5","author":"Park","year":"2004","journal-title":"Kor J Radiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thorac Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discovery"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.717319","article-title":"Identification and validation of a tumor microenvironment-related gene signature in hepatocellular carcinoma prognosis","volume":"12","author":"Huang","year":"2021","journal-title":"Front Genet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.3390\/ijms23073778","article-title":"Tumor microenvironment of hepatocellular carcinoma: Challenges and opportunities for new treatment options","volume":"23","author":"Sas","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1038\/s41467-021-24010-1","article-title":"Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma","volume":"12","author":"Ho","year":"2021","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/cancers13020238","article-title":"The new immuno-Oncology-Based therapies and their perspectives in hepatocellular carcinoma","volume":"13","author":"Merle","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"BSR20204312","DOI":"10.1042\/BSR20204312","article-title":"CXCL2\/10\/12\/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma","volume":"41","author":"Lin","year":"2021","journal-title":"Biosci Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.998736\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T05:26:54Z","timestamp":1664947614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.998736\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":62,"alternative-id":["10.3389\/fonc.2022.998736"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.998736","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"article-number":"998736"}}